The main adverse events associated with GLP-1 receptor agonists are gastrointestinal (GI) in nature, primarily nausea, vomiting, and diarrhea (Table 2)
MOTS-C directly addresses this by optimizing mitochondrial ATP production
STEP 1 showed 14.9% body weight reduction at 2.4 mg weekly SELECT trial : Cardiovascular outcomes study showing 20% MACE reduction in patients with obesity and established CVD without diabetes FLOW trial : Kidney outcomes data demonstrating renal protective effects Oral formulation : Rybelsus provides an oral dosing option at 7-14 mg daily Real-world data : Millions of prescriptions written, providing extensive post-marketing safety surveillance Survodutide Research# Survodutide's evidence base is growing but not yet mature: Phase 2 obesity trial : Demonstrated dose-dependent weight loss up to approximately 19% body weight reduction, exceeding typical GLP-1 monotherapy results Phase 2 MASH data : Histological improvement in liver biopsies, including reduction in hepatic steatosis and inflammation scores Phase 3 programs : Active Phase 3 trials for both obesity and MASH, with results anticipated to define the compound's clinical profile Mechanism validation : Clinical data support the dual mechanism concept, with evidence of both appetite reduction and increased energy expenditure Limitation : No regulatory approvals
Waqas SA, Sohail MU, Saad M, Minhas AMK, Greene SJ, Fudim M, et al
1.8 million glutax whitening needles 10 plant extracts are white and white
